bluebird bio Completes Planned Business Separation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
November 8, 2021 5:11 AM ESTMorgan Stanley analyst Matthew Harrison downgraded bluebird bio (NASDAQ: BLUE) from Equalweight to Underweight with a price target of $11.00 (from $19.00).
The analyst comments "Bluebird has developed a robust portfolio of genetherapies where we expect approval in 2022/2023. However, we believe the ultimate market for... More
